Table 4.
Antihypertensive treatment, comorbidity, and risk factors in patients known with hypertension
| Antihypertensive treatment | Controlled hypertension (n = 467) |
Uncontrolled hypertension (n = 483) |
P-value |
|---|---|---|---|
| No treatmenta | 4% (n = 17) | 11% (n = 52) | <0.001 |
| Mean number of antihypertensive drugsa | 2.0±1.0 | 1.6±1.0 | <0.001 |
| Angiotensin converting enzyme inhibitora | 42% (n = 198) | 38% (n = 184) | NS |
| Angiotensin receptor antagonista | 28% (n = 130) | 23% (n = 111) | NS |
| Calcium channel blockera | 36% (n = 166) | 34% (n = 162) | NS |
| Thiazida | 52% (n = 242) | 42% (n = 205) | <0.01 |
| Furosemidea | 6% (n = 28) | 4% (n = 19) | NS |
| Spironolactone a | 3% (n = 14) | 1% (n = 5) | <0.05 |
| Amiloride a | 1% (n = 5) | 1% (n = 3) | NS |
| Alpha-blockera | 1% (n = 5) | 1% (n = 7) | NS |
| Beta-blockera | 26% (n = 121) | 19% (n = 93) | <0.05 |
| Minoxidila | 0% (n = 0) | 0% (n = 1) | NS |
| Moxonidina | 0% (n = 1) | 0% (n = 1) | NS |
| Male | 46% (n = 215) | 51% (n = 244) | NS |
| Diabetesa | 14% (n = 66) | 12% (n = 56) | NS |
| Kidney diseasea | 2% (n = 9) | 2% (n = 7) | NS |
| Prior ischemic heart diseasea | 12% (n = 55) | 7% (n = 33) | <0.01 |
| Prior strokea | 6% (n = 28) | 6% (n = 28) | NS |
| Current smokera | 15% (n = 69) | 18% (n = 83) | NS |
Comparison of antihypertensive treatment in patients known with hypertension depending on whether the patient had controlled (HBP < 135/85) or uncontrolled hypertension (HBP ≥135/85). Data are reported as percentage (number) of study participants. Pearson’s chi-squared test used for comparisons of categorical variables. Student’s t-test used for comparison of unpaired continuous variables.
aSelf-reported data.